Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02025803 · ClinicalTrials.gov registry record · Phase 1
A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Taiho Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT02025803 is a Phase 1 study that has completed, run by Taiho Oncology. The registered enrollment target is 60 participants.
The verdict
NCT02025803, a Phase 1 study, has completed, sponsored by Taiho Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this exploratory study is to investigate the safety and determine the maximum tolerated dose (MTD) of TAS-114 in combination with capecitabine in patients with advanced solid tumors for which the patients have no available therapy likely to convey clinical benefit.
Interventions
- DRUG TAS-114/capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-11 |
| Est. Completion | 2017-07-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02025803
The ClinicalTrials.gov registry entry for NCT02025803 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAS-114/capecitabine is the first listed.
NCT02025803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02025803 about?
NCT02025803 is a clinical study titled "A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors". The purpose of this exploratory study is to investigate the safety and determine the maximum tolerated dose (MTD) of TAS-114 in combination with capecitabine in patients with advanced solid tumors for which the patients have no available therapy likely to convey clinical benefit.
What is the current status of trial NCT02025803?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2012-11. Estimated completion is 2017-07-07.
What interventions are being tested in trial NCT02025803?
The interventions under investigation include: TAS-114/capecitabine (DRUG).
Who is sponsoring clinical trial NCT02025803?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.